Trexquant Investment LP Purchases 308,516 Shares of REGENXBIO Inc. $RGNX

Key Points

• Trexquant Investment LP significantly increased its stake in REGENXBIO Inc. by 205.6%, acquiring an additional 308,516 shares, bringing its total holdings to 458,538 shares worth approximately $3.28 million.
• Analysts have mixed views on REGENXBIO, with HT Wainwright assigning a "buy" rating and a $34.00 price target, while others like Royal Bank of Canada lowered their price target from $21.00 to $17.00.
• REGENXBIO reported disappointing financial results, posting a quarterly loss of ($1.38) EPS, which was below the consensus estimate, and revenues of just $21.36 million against expectations of $40.87 million.

Trexquant Investment LP increased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 205.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 458,538 shares of the biotechnology company's stock after purchasing an additional 308,516 shares during the quarter. Trexquant Investment LP owned 0.91% of REGENXBIO worth $3,279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FNY Investment Advisers LLC bought a new position in shares of REGENXBIO during the first quarter valued at $35,000. Brooklyn Investment Group lifted its holdings in shares of REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,466 shares in the last quarter. Laurion Capital Management LP bought a new position in shares of REGENXBIO during the fourth quarter valued at $79,000. Pallas Capital Advisors LLC bought a new position in shares of REGENXBIO during the first quarter valued at $74,000. Finally, Tower Research Capital LLC TRC lifted its holdings in REGENXBIO by 442.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 10,714 shares during the period. 88.08% of the stock is owned by institutional investors.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX traded up $0.29 during trading on Friday, hitting $9.71. The company had a trading volume of 609,824 shares, compared to its average volume of 643,702. The company has a fifty day simple moving average of $8.65 and a two-hundred day simple moving average of $8.18. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $13.48. The stock has a market cap of $490.45 million, a price-to-earnings ratio of -2.82 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. The business had revenue of $21.36 million for the quarter, compared to analysts' expectations of $40.87 million. On average, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Ratings Changes

RGNX has been the topic of several recent research reports. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Friday, August 8th. Barclays decreased their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a research note on Tuesday, August 19th. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Finally, Royal Bank Of Canada decreased their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $28.38.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.